Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer
Lehmann, U, Hasemeier, B, Christgen, M, Müller, M, Römermann, D, Länger, F, Kreipe, H
Published in The Journal of pathology (01.01.2008)
Published in The Journal of pathology (01.01.2008)
Get full text
Journal Article
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
Nitz, U A, Gluz, O, Christgen, M, Grischke, E-M, Augustin, D, Kuemmel, S, Braun, M, Potenberg, J, Kohls, A, Krauss, K, Stefek, A, Schumacher, C, Forstbauer, H, Reimer, T, Fischer, H, Liedtke, C, Wuerstlein, R, Schumacher, J, Kates, R, Kreipe, H, Harbeck, N
Published in Annals of oncology (01.11.2017)
Published in Annals of oncology (01.11.2017)
Get full text
Journal Article
Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18
Raap, M., Gierendt, L., Werlein, C., Kuehnle, E., Kreipe, H. H., Christgen, M.
Published in Journal of molecular histology (01.12.2021)
Published in Journal of molecular histology (01.12.2021)
Get full text
Journal Article
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial
Gluz, O., Kuemmel, S., Nitz, U., Braun, M., Lüdtke-Heckenkamp, K., von Schumann, R., Darsow, M., Forstbauer, H., Potenberg, J., Uleer, C., Grischke, E.M., Aktas, B., Schumacher, C., zu Eulenburg, C., Kates, R., Jóźwiak, K., Graeser, M., Wuerstlein, R., Baehner, R., Christgen, M., Kreipe, H.H., Harbeck, N.
Published in Annals of oncology (01.06.2023)
Published in Annals of oncology (01.06.2023)
Get full text
Journal Article
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
Martín, M., Stecklein, S.R., Gluz, O., Villacampa, G., Monte-Millán, M., Nitz, U., Cobo, S., Christgen, M., Brasó-Maristany, F., Álvarez, E.L., Echavarría, I., Conte, B., Kuemmel, S., Bueno-Muiño, C., Jerez, Y., Kates, R., Cebollero, M., Kolberg-Liedtke, C., Bueno, O., García-Saenz, J.Á., Moreno, F., Grischke, E.-M., Forstbauer, H., Braun, M., Warm, M., Hackmann, J., Uleer, C., Aktas, B., Schumacher, C., Wuerstleins, R., Graeser, M., Eulenburg, C., Kreipe, H.H., Gómez, H., Massarrah, T., Herrero, B., Paré, L., Bohn, U., López-Tarruella, S., Vivancos, A., Sanfeliu, E., Parker, J.S., Perou, C.M., Villagrasa, P., Prat, A., Sharma, P., Harbeck, N.
Published in Annals of oncology (15.10.2024)
Published in Annals of oncology (15.10.2024)
Get full text
Journal Article
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”: [Annals of Oncology 28 (2017) 2768-2772]
Nitz, U.A., Gluz, O., Christgen, M., Grischke, E.-M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H., Harbeck, N.
Published in Annals of oncology (01.03.2022)
Published in Annals of oncology (01.03.2022)
Get full text
Journal Article
Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial
Gluz, O., Nitz, U., Liedtke, C., Christgen, M., Grischke, E.-M., Forstbauer, H., Braun, M., Warm, M., Hackmann, J., Uleer, C., Aktas, B., Schumacher, C., Lindner, C., Kümmel, S., Kates, R.E., Potenberg, J., Staib, P., Wuerstlein, R., Kreipe, H.H., Harbeck, N.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
Nitz, U.A., Gluz, O., Christgen, M., Grischke, E. -M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H., Harbeck, N.
Published in Annals of oncology (01.11.2017)
Published in Annals of oncology (01.11.2017)
Get full text
Journal Article
Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes
Gluz, O, Nitz, U, Christgen, M, Kates, R, Clemens, M, Nuding, B, Shak, S, Würstlein, R, Kreipe, H, Harbeck, N
Published in Breast (Edinburgh) (01.03.2017)
Published in Breast (Edinburgh) (01.03.2017)
Get full text
Journal Article
1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial
Gluz, O, Nitz, U, Kreipe, H.H, Christgen, M, Kates, R.E, Hofmann, D, Shak, S, Clemens, M, Kraemer, S, Aktas, B, Kuemmel, S, Reimer, T, Kusche, M, Heyl, V, Lorenz-Salehi, F, Just, M, Liedtke, C, Wuerstlein, R, Harbeck, N
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study
Gluz, O, Nitz, U, Christgen, M, Kreipe, H, Kates, R.E, Kuemmel, S, Braun, M, Schumacher, C, Wuerstlein, R, Harbeck, N
Published in Breast (Edinburgh) (01.03.2015)
Published in Breast (Edinburgh) (01.03.2015)
Get full text
Journal Article
Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells
TRAUZOLD, A, SCHMIEDEL, S, KALTHOFF, H, RÖDER, C, TAMS, C, CHRISTGEN, M, OESTERN, S, ARLT, A, WESTPHAL, S, KAPISCHKE, M, UNGEFROREN, H
Published in British journal of cancer (03.11.2003)
Published in British journal of cancer (03.11.2003)
Get full text
Journal Article
LBA17 Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early breast cancer (EBC): WSG-TP-II trial
Gluz, O., Nitz, U.A., Christgen, M., Kummel, S., Holtschmidt, J., Schumacher, J., Hartkopf, A.D., Luedtke-Heckenkamp, K., Just, M., von Schumann, R., Polata, S., Schinköthe, T., Graeser-Mayer, M.K., Kates, R.E., Würstlein, R., Kreipe, H., Harbeck, N.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
LBA24 Multiparametric prognostic score in early HR+/HER2- breast cancer: Impact of recurrence score, clinical-pathological factors, gene mutations and histology
Gluz, O., Christgen, M., zu Eulenburg, C., Nitz, U.A., Kummel, S., Braun, M., Aktas, B., Luedtke-Heckenkamp, K., Forstbauer, H., Grischke, E-M., Schumacher, C., Baehner, R.F.L., Kates, R.E., Graeser, M., Würstlein, R., Kreipe, H., Harbeck, N.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
237MO TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy
Jimenez, M. Martin, Gluz, O., Villacampa, G., Lopez-Tarruella Cobo, S., Nitz, U.A., Cobo, S., Brasó-Maristany, F., Christgen, M., Gilarranz, Y. Jerez, Kummel, S., Conte, B., Diaz-Guardamino, I. Echavarria, Graeser-Mayer, M.K., Kreipe, H., Del Monte-Millan, M., Lopez, B. Herrero, Perou, C.M., Brunet, L. Pare, Prat, A., Harbeck, N.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial
Graeser, M., Gluz, O., Biehl, C., Ulbrich-Gebauer, D., Palatty, J., Christgen, M., Kuemmel, S., Grischke, E-M., Augustin, D., Braun, M., Potenberg, J., Wuerstlein, R., Eulenburg, C., Kates, R., Kolberg-Liedtke, C., Feuerhake, F., Kreipe, H., Nitz, U., Harbeck, N.
Published in Annals of oncology (01.05.2021)
Published in Annals of oncology (01.05.2021)
Get full text
Journal Article